Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.

Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NM, Lau A, Newell DR, Curtin NJ.

Mol Cancer Ther. 2013 Jun;12(6):959-67. doi: 10.1158/1535-7163.MCT-12-0707. Epub 2013 Mar 19.

2.

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC, Curtin NJ.

Cancer Res. 2006 May 15;66(10):5354-62.

3.

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.

Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC.

Cancer Res. 2004 Dec 15;64(24):9152-9.

4.

Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.

Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear K, Slade A, Thommes P, Martin NM, Newell DR, Smith GC, Curtin NJ.

Mol Cancer Ther. 2012 Aug;11(8):1789-98. doi: 10.1158/1535-7163.MCT-11-0535. Epub 2012 May 10.

5.

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M.

Sci Adv. 2018 Jun 20;4(6):eaat1719. doi: 10.1126/sciadv.aat1719. eCollection 2018 Jun.

6.

Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.

Huang CY, Hsieh FS, Wang CY, Chen LJ, Chang SS, Tsai MH, Hung MH, Kuo CW, Shih CT, Chao TI, Chen KF.

Eur J Cancer. 2018 Oct;102:10-22. doi: 10.1016/j.ejca.2018.07.010. Epub 2018 Aug 10.

PMID:
30103095
7.

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang LZ, Webber SE, Curtin NJ.

Mol Cancer Ther. 2007 Mar;6(3):945-56.

8.

Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites.

Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D.

Ann Oncol. 2003 Jun;14(6):938-45.

PMID:
12796033
9.

The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53.

Thomas A, Perry T, Berhane S, Oldreive C, Zlatanou A, Williams LR, Weston VJ, Stankovic T, Kearns P, Pors K, Grand RJ, Stewart GS.

Oncogene. 2015 Jun;34(25):3336-48. doi: 10.1038/onc.2014.266. Epub 2014 Aug 18.

PMID:
25132271
10.

Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells.

Wang Y, Yang L, Zhang J, Zhou M, Shen L, Deng W, Liang L, Hu R, Yang W, Yao Y, Zhang H, Zhang Z.

Int J Oncol. 2018 Oct;53(4):1667-1680. doi: 10.3892/ijo.2018.4514. Epub 2018 Aug 3.

PMID:
30085332
11.

SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.

Zhao P, Chen L, Li LH, Wei ZF, Tong B, Jia YG, Kong LY, Xia YF, Dai Y.

BMC Cancer. 2014 Dec 19;14:987. doi: 10.1186/1471-2407-14-987.

12.

Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.

Gil del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, Xie XJ, Bachoo R, Li L, Habib AA, Burma S.

Clin Cancer Res. 2014 Mar 1;20(5):1235-48. doi: 10.1158/1078-0432.CCR-13-1607. Epub 2013 Dec 23.

13.

ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.

Subhash VV, Tan SH, Yeo MS, Yan FL, Peethala PC, Liem N, Krishnan V, Yong WP.

Mol Cancer Ther. 2016 Dec;15(12):3087-3096. Epub 2016 Sep 16.

14.

USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.

Agathanggelou A, Smith E, Davies NJ, Kwok M, Zlatanou A, Oldreive CE, Mao J, Da Costa D, Yadollahi S, Perry T, Kearns P, Skowronska A, Yates E, Parry H, Hillmen P, Reverdy C, Delansorne R, Paneesha S, Pratt G, Moss P, Taylor AMR, Stewart GS, Stankovic T.

Blood. 2017 Jul 13;130(2):156-166. doi: 10.1182/blood-2016-12-758219. Epub 2017 May 11.

PMID:
28495793
15.

D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.

Juang SH, Lung CC, Hsu PC, Hsu KS, Li YC, Hong PC, Shiah HS, Kuo CC, Huang CW, Wang YC, Huang L, Chen TS, Chen SF, Fu KC, Hsu CL, Lin MJ, Chang CJ, Ashendel CL, Chan TC, Chou KM, Chang JY.

Mol Cancer Ther. 2007 Jan;6(1):193-202.

16.

Transcription-dependent activation of ataxia telangiectasia mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison.

Sakasai R, Teraoka H, Takagi M, Tibbetts RS.

J Biol Chem. 2010 May 14;285(20):15201-8. doi: 10.1074/jbc.M110.101808. Epub 2010 Mar 19.

17.

The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect.

Zhang T, Shen Y, Chen Y, Hsieh JT, Kong Z.

Int J Radiat Biol. 2015 Apr;91(4):368-78. doi: 10.3109/09553002.2015.1001531. Epub 2015 Feb 6.

PMID:
25585815
18.

Resveratrol induces DNA damage in colon cancer cells by poisoning topoisomerase II and activates the ATM kinase to trigger p53-dependent apoptosis.

Demoulin B, Hermant M, Castrogiovanni C, Staudt C, Dumont P.

Toxicol In Vitro. 2015 Aug;29(5):1156-65. doi: 10.1016/j.tiv.2015.04.015. Epub 2015 May 5.

PMID:
25952326
19.

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.

Vendetti FP, Lau A, Schamus S, Conrads TP, O'Connor MJ, Bakkenist CJ.

Oncotarget. 2015 Dec 29;6(42):44289-305. doi: 10.18632/oncotarget.6247.

20.

Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin.

Zimmermann M, Arachchige-Don AS, Donaldson MS, Dallapiazza RF, Cowan CE, Horne MC.

J Biol Chem. 2012 Jun 29;287(27):22838-53. doi: 10.1074/jbc.M112.376855. Epub 2012 May 15.

Supplemental Content

Support Center